Table of Contents
Viscosupplementation is the treatment for Osteoarthritis which is the most common joint disease affecting the middle age to elderly section of the people. In this method, doses of hyaluronic acid are given through injections in affected joints in the synovial fluid. The course of treatment can be of single injection formulation or subsequent doses of multiple-injection (three-injection) formulation. Viscosupplementation helps in reducing pain and improving joint movements.
Currently the market for Hyaluronic Acid Viscosupplementation is estimated to be around $2 billion and is poised to grow in the future. The steady growth of 6.5% can be attributed to the rise in the geriatric population globally as Osteoarthritis affects the aging population to a great extent. Also, the rise in cases of obesity worldwide has led to higher prevalence of Osteoarthritis leading to a growing demand for its treatment. These factors will provide a strong impetus to the growth of Hyaluronic Acid Viscosupplementation market. In India, Osteoarthritis is prevalent amongst 30-35% of its aging population which is a driving factor for the growth of Hyaluronic Acid Viscosupplementation market in the country (Satelli, 2014).
Injection site pain and joint pain swelling can be the restraining factors for the growth of the Hyaluronic Acid Viscosupplementation market. The global market for Hyaluronic Acid Viscosupplementation is expected to grow with the intensive research being conducted on the usage of Hyaluronic Acid and Viscosupplmentation for different types of joint treatment.
Please note: this report requires certain updates. We have all the information available but require 2 business days to complete the process and ensure it is as up-to-date as possible.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Pipeline Overview Idiopathic pulmonary fibrosis (IPF) is referred to as progressive and chronic interstitial pneumonia without known cause. Pulmonary fibrosis is a disease in which tissue profound in lungs ...
Chronic Kidney Disease (CKD) Drugs Market (Drug Class - ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis - stimulating Agents (ESAs), and Diuretics; ...
The global cholesterol testing services market is expected to reach USD 17.5 billion by 2021 from USD 11.9 billion in 2016, growing at a CAGR of 8% during the forecast period. This market is segmented ...